Eclipsebio Acquires Terrain Bio to Expand Its End-to-End AI Platform for the Design, Manufacturing, and Validation of RNA Therapeutics ...

Jan 6 (Reuters) - Variant Bio, a private biotech firm, said on Tuesday it has launched a platform that uses artificial intelligence on genetic data to discover new ‌drug candidates to send into human ...

Accelerated drug discovery and development platform Converge Bio Inc. today announced it has raised $25 million in early-stage funding to develop better drugs for pharmaceutical companies and open up ...

Converge Bio, the AI platform for accelerated drug discovery and development, announced today $25 million in Series A funding, bringing its total raised to $30 million. The round was led by Bessemer ...

"CGIE (TM) is being built as future-facing infrastructure rather than a point solution," said Yusuf Henriques, Founder and CEO of IndyGeneUS Bio. "Our objective is to establish the AI×Bio Factory--the ...

Converge Bio CEO Dov Gertz said, "The conversation needs to shift from models to AI systems. Unlike ChatGPT, you can’t simply ...

YD Bio Limited ('YD Bio” or the 'Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced that the ...

Artificial intelligence (AI) is edging closer to the bioreactor. But its progress is being slowed by an unglamorous obstacle: the disarray of bioprocessing data. According to Phil Mounteney, vice ...

Kevin Murphy has taken over as the new chief AI officer at NASA after its inaugural CAIO, David Salvagnini, departed the role.